The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis

Atherosclerosis

Volumn 147, Issue 2, 1999, Pages 379-386

  Chao, Chia Lun ^a   Tsai, Hui Hsin ^a   Lee, Chii Ming ^a   Hsu, Su Ming ^a   Kao, Jau Tsuen ^b   Chien, Kuo Liong ^a   Sung, Fung Chang ^c   Lee, Yuan Teh ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Coronary artery disease; Hyperhomocysteinemia; Methylenetetrahydrofolate reductase

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2);

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TAIWAN;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BASE SEQUENCE; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; FEMALE; HEALTH SURVEYS; HUMANS; HYPERHOMOCYSTEINEMIA; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; OXIDOREDUCTASES ACTING ON CH-NH GROUP DONORS; POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; TAIWAN;

EID: 0032714729     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00208-7     Document Type: Article

References (38)

1. Stampfer M.J., Malinow M.R., Willett W.C., Newcomer L.M., Upson B., Ullmann D. et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc. 268:1992;877-881.
2. Mayer E.L., Jacobsen D.W., Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol. 27:1996;517-527.
3. McCully K.S. Homocysteine and vascular disease. Nat Med. 2:1996;386-389.
4. Kang S.S., Wong P.W.K., Norusis M. Homocysteinemia due to folate deficiency. Metabolism. 36:1987;458-462.
5. Kang S.S., Zhou J., Wong P.W.K., Susmano A., Sora J., Norusis M. et al. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet. 48:1991;536-545.
6. Engbersen A.M., Franken D.G., Boers G.H., Stevens E.M.B., Trijbels F.J.M., Blom G.H.J. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet. 56:1995;142-150.
7. Goyette P., Sumner J.S., Milos R., Duncan A.M.V., Rosenblatt D.S., Matthews R.G. et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet. 7:1994;195-200.
8. Goyette P., Frosst P., Rosenblatt D.S., Rozen R. Seven novel mutations in the methylenetetrahydrofolate reductase gene and genotype/phenotype correlations in severe methylenetetrahydrofolate reductase deficiency. Am J Hum Genet. 56:1995;1052-1059.
9. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G. et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 10:1995;111-113.
10. Morita H., Taguchi J.I., Kurihara H., Kitaoka M., Kaneda H., Kurihara Y. et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation. 95:1997;2032-2036.
11. Kluijtmans L.A.J., Kastelein J.J.P., Lindemans J., Boers G.H.J., Heil S.G., Bruschke A.V.G. et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 96:1997;2573-2577.
12. Brugada R., Marian A.J. A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis. 128:1997;107-112.
13. Van Bockxmeer F.M., Mamotte C.D.S., Vasikaran S.D., Taylor R.R. Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation. 95:1997;21-23.
14. Anderson J.L., King G.J., Thomson M.J., Todd M., Bair T.L., Muhlestein J.B. et al. A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction. J Am Coll Cardiol. 30:1997;1206-1211.
15. Malinow M.R., Nieto F.J., Szklo M., Chambless L.E., Bond G. Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The atherosclerosis risk in communities study. Circulation. 87:1993;1107-1113.
16. Kang S.S., Passen E.L., Ruggie N., Wong P.W.K., Sora H. Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 88(1):1993;1463-1469.
17. von Eckardstein A., Malinow M.R., Upson B., Heinrich J., Schulte H., Schönfeld R. et al. Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb. 14:1994;460-464.
18. Brown B.G., Zhao X.Q., Sacco D.E., Albers J.J. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation. 87:1993;1781-1791.
19. Austen W.G., Edwards J.E., Frye R.L., Gensini G.G., Gott V.L., Griffith L.S.C. et al. AHA Committee Report: a reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for grading of coronary artery disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 51:1975;7-40.
20. Gensini G.G. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 51:1983;606.
21. Chao C.L., Huang P.J., Wu C.C., Shen S.J., Chieng P.U., Su C.T. et al. Correlation between quantitative severity of stress thallium-201 myocardial perfusion defect and severity of coronary stenosis. J Formos Med Assoc. 95:1996;105-109.
22. Sullivan D.R., Marwick T.H., Freedman S.B. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am Heart J. 119:1990;1262-1267.
23. Fortin L.J., Genest J. Jr Measurement of homocyst(e)ine in the prediction of atherosclerosis. Clin Biochem. 28:1995;155-162.
24. Schwartz S.M., Siscovick D.S., Malinow M.R., Rosendaal F.R., Beverly R.K., Hess D.L. et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation. 96:1997;412-417.
25. McAndrew P.E., Brandt J.T., Pearl D.K., Prior T.W. The incidence of the gene for thermolabile methylenetetrahydrofolate reductase in African Americans. Thromb Res. 83:1996;195-198.
26. Ma J., Stampfer M.J., Hennekens C.H., Frosst P., Selhub J., Horsford J. et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 94:1996;2410-2416.
27. 677T mutation. Arterioscler Thromb Vasc Biol. 16:1996;878-882.
28. Jacques P.F., Bostom A.G., Williams R.R., Ellison R.C., Eckfeldt J.H., Rosenberg I.H. et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 93:1996;7-9.
29. Boers G.H.J., Smals A.G.H., Trijbels F.J.M., Fowler B., Bakkeren J.A.J.M., Schoonderwaldt H.C. et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med. 313:1985;709-715.
30. Boushey C.J., Beresford S.A.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. J Am Med Assoc. 274:1995;1049-1057.
31. Verhoef P., Kok F.J., Kruyssen D.A.C.M., Schouten E.G., Witteman J.C.M., Grobbee D.E. et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 17:1997;989-995.
32. Hutter A.M. Jr Is there a left main equivalent? Circulation. 62:1980;207-211.
33. Azen S.P., Mack W.J., Cashin-Hemphill L., LaBree L., Shircore A.M., Selzer R.H. et al. Progression of coronary artery disease predicts clinical coronary events: long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation. 93:1996;34-41.
34. Herd J.A., Ballantyne C.M., Farmer J.A., Ferguson J. III, Jones P.H., West M.S. et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 80:1997;278-286.
35. Falk E. Why do plaques rupture? Circulation. 86(Suppl III):1992;30-42.
36. Solberg L.A., Strong J.P. Risk factors and atherosclerosis: a review of autopsy studies. Arteriosclerosis. 3:1983;187-198.
37. Nakagomi A., Celermajer D.S., Lumley T., Freedman S.B. Angiographic severity of coronary narrowing is a surrogate marker for the extent of coronary atherosclerosis. Am J Cardiol. 78:1996;516-519.
38. Glueck C.J., Shaw P., Lang J.E., Tracy T., Sieve-Smith L., Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol. 75:1995;132-136.